ATRA

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is a clinical-stage biotechnology company founded in 2012 and headquartered in South San Francisco, California. The company went public in October 2014 and specializes in developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. Atara has evolved from a broad-based immunotherapy developer to a more focused organization following strategic partnerships and operational restructuring in recent years.